TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02903771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: Dose Escalation of Cantrixil
Description: Cantrixil will be administered via the intraperitoneal route only. The dose of study drug that each participant will receive will depend on how far the study has progressed when the participant enrols. There are 9 potential doses of Cantrixil, they are 0.06, 0.12, 0.24 (starting dose), 0.6, 1.25, 2.5, 5, 10, or 20 mg/kg. The dose each participant receives will remain the same during the study, unless it needs to be reduced for safety reasons. The dose will not be increased.~Each participant will receive the study drug once a week during the first two cycles; each cycle is 21-days (three weeks); the MTD will be determined during Cycle 1 only. If after two cycles of monotherapy, the patient tolerates Cantrixil adequately, they may continue to receive Cantrixil once a week and will also begin combination chemotherapy for another 6 cycles. Participants will receive no more than 8 cycles of study drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Expansion Cohort of Cantrixil
Description: Once the MTD has been established, an expansion cohort will be recruited at the MTD. An additional 12 patients will be recruited in this cohort on top of those recruited in Part A at the MTD. These patients will be subjected to the same intervention described in Part A with 2 cycles of monotherapy followed by up to 6 cycles of combination therapy.
Study: NCT03631940

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Milking
Description: At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early Cord Clamping
Description: The umbilical cord is clamped within 60 seconds of delivery.
Study: NCT03884829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYC140
Description: CYC140 single agent
Study: NCT02674035

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Correction of diastasis of the rectus abdominis muscles
Description: Thirty women with similar abdominal deformities, who had had at least one pregnancy, were randomized into three groups to undergo abdominoplasty. Plication of the anterior rectus sheath was performed in two layers with 2-0 monofilament nylon suture (control group) or in a single layer with either a continuous 2-0 monofilament nylon suture (group I) or using a continuous barbed suture (group II). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Correction of diastasis of the rectus abdominis muscles
Description: Thirty women with similar abdominal deformities, who had had at least one pregnancy, were randomized into three groups to undergo abdominoplasty. Plication of the anterior rectus sheath was performed in two layers with 2-0 monofilament nylon suture (control group) or in a single layer with either a continuous 2-0 monofilament nylon suture (group I) or using a continuous barbed suture (group II). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Correction of diastasis of the rectus abdominis muscles
Description: Thirty women with similar abdominal deformities, who had had at least one pregnancy, were randomized into three groups to undergo abdominoplasty. Plication of the anterior rectus sheath was performed in two layers with 2-0 monofilament nylon suture (control group) or in a single layer with either a continuous 2-0 monofilament nylon suture (group I) or using a continuous barbed suture (group II). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
Study: NCT03891134

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Branched Chain Amino Acid
Description: Participants were purposively sampled to receive one sachet enriched BCAA twice a day(7.2g) for 5 weeks.
Study: NCT04897997

Intervention type: PROCEDURE
Intervention: coronarography and angioplasty
Description: selective angiography of the coronaries and angioplasty of significant culprit lesion(s)

Intervention type: PROCEDURE
Intervention: coronarography and angioplasty
Description: selective angiography of the coronaries and angioplasty of significant culprit lesion(s)

Intervention type: PROCEDURE
Intervention: coronarography and angioplasty
Description: selective angiography of the coronaries and angioplasty of significant culprit lesion(s)

Intervention type: PROCEDURE
Intervention: coronarography and angioplasty
Description: selective angiography of the coronaries and angioplasty of significant culprit lesion(s)
Study: NCT01285323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reslizumab
Description: Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (acetate sucrose buffer), administered intravenously (iv) once every 4 weeks for a total of 13 doses.
Study: NCT02121158

Intervention type: DEVICE
Group type: OTHER
Intervention: Implantable Cardioverter Defibrillator
Description: The ICD and lead(s) will be FDA-approved.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Therapy
Description: Guidance on lifestyle modification, exercise training, and disease management including review of American Heart Association (AHA) Guidelines for Primary Prevention of Cardiovascular Disease and Stroke.
Study: NCT04420234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: narfurine hydrochloride orally disintegrating tablets
Description: Subjects swallowed 2 tablets of test drug (2.5 µg/tablet) with saliva at about 8:00 AM on D1; swallowed 2 tablets of test drug (2.5 µg/tablet) with saliva at about 8:00 AM starting on D4. Dosing for 7 consecutive days (D10 last dose in the morning).
Study: NCT00736541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: The patients in the NAC group will receive a loading dose of 140 mg/kg IV of NAC over one hour at the start of the surgery. Thereafter, NAC will be repeated every 4 hours at a dose of 70 mg/kg IV, for a total of 13 doses
Study: NCT01950182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy combined with trastuzumab
Description: Tamoxifen or aromatase inhibitors (Anastrozole, Letrozole, or Exemestane) combined with trastuzumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy combined with trastuzumab
Description: Capecitabine , Vinorelbine, or Gemcitabine combined with trastuzumab
Study: NCT01426100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 40/2.5mg
Description: Fixed dose combination of Telmisartan 40mg and S-Amlodipine 2.5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 40/5mg
Description: Fixed dose combination of Telmisartan 40mg and S-Amlidioine 5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan 80mg
Description: Telmisartan 80mg monotherapy
Study: NCT02042417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INRatio2 and CoaguChek
Study: NCT01700413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Study: NCT02862678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diffusion-weighted MRI
Description: Two diffusion-weighted MRI will be performed (one 8 days before chemoradiotherapy treatment and one 3 months after the end of chemoradiotherapy treatment).
Study: NCT02212015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib + Paclitaxel
Description: pazopanib in combination with paclitaxel in the treatment of patients with advanced or metastatic angiosarcoma.
Study: NCT03651310

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Listening Group
Description: Waiting in preoperative area with music listening.
Study: NCT04602221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, Film-coated tablet
Study: NCT02780843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Tomography
Description: Standard Operational Plan at admission: CT and CT-angiography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Standard Operational Plan at admission: Diffusion Weighted Imaging (DWI), T2-FLAIR, Gradient and arterial Time-of Flight (TOF)
Study: NCT03448406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet
Study: NCT00015210

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nefazodone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nefazodone

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychosocial Treatment
Description: All subjects attended a weekly 1-hour therapy session during the 8 week treatment period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial Treatment
Description: All subjects attended a weekly 1-hour therapy session during the 8 week treatment period.
Study: NCT04369404

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic organ prolapse decision aid
Description: Paper-based educational tool to guide shared decision making conversations for treatment of pelvic organ prolapse

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress urinary incontinence decision aid
Description: Paper-based educational tool to guide shared decision making conversations for treatment of stress urinary incontinence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overactive bladder decision aid
Description: Paper-based educational tool to guide shared decision making conversations for treatment of overactive bladder.
Study: NCT03772886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peanut Ball
Description: A peanut shaped exercise ball.
Study: NCT03177317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 8mg IV before chemotherapy on cycle 1 day 1~Once the complete response is achieved, the dose of dexamethasone will be reduced by 2 mg in the next cycle.
Study: NCT02704325

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAVrh74.MCK.GALGT2
Description: Direct intramuscular injection of rAAVrh74.MCK.GALGT2 transferred to the extensor digitorum brevis muscle (EDB) of one foot and the other side receiving saline alone.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLACEBO (Saline)
Description: Direct intramuscular injection of rAAVrh74.MCK.GALGT2 transferred to the extensor digitorum brevis muscle (EDB) of one foot and the OTHER side receiving saline alone.
Study: NCT03405792

Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide (TMZ)
Description: Patients will begin treatment with adjuvant TMZ at least 4 weeks but no more than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the latter of the two). A minimum of 6 and maximum of 12 cycles of adjuvant TMZ will be given depending on tolerability and toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: Patients will begin treatment with adjuvant TMZ at least 4 weeks but no more than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the latter of the two). A minimum of 6 and maximum of 12 cycles of adjuvant TMZ will be given depending on tolerability and toxicity.

Intervention type: DEVICE
Group type: OTHER
Intervention: Optune System
Description: Patients will undergo 24-months of planned treatment with Optune therapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune System
Description: Patients will undergo 24-months of planned treatment with Optune therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be given intravenously every 3 weeks beginning on Day 1 of Cycle 2 of adjuvant TMZ. Treatment with pembrolizumab every 3 weeks until first disease progression or unacceptable toxicities or 2 years, whichever comes first.
Study: NCT03003026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel task-specific bike skills training program
Description: Participants randomised to the intervention group will participate in a novel task-specific bike skills training program. The intervention involves seven key components: it is group-based, intensive (2 hours per day for 3 days plus a home program for the remaining days of the one week period), task-specific, goal-directed, and therapist led, with parent involvement and conducted in an ecological setting. Each program will be run by a physiotherapist and allied health assistant during the school holidays.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parent-led home-based bike skills training program
Description: The comparison group will involve a parent-led home-based bike skills training program. Parents of children randomized to the comparison group will receive written information and telephone support from a physiotherapist on training bike skills. They will be encouraged to work with their child towards their bike skills goals for at least 30-45 minutes per day over a one week period during the school holidays in home and community environments.
Study: NCT03249207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IL-1Ra
Description: Doses to be administered subcutaneously (SC) twice daily (12 hourly) starting within 72 hours of ictus (onset of symptoms) for a maximum of 21 days from ictus (or sooner if discharged from neurosurgical centre).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IL-1Ra Placebo
Description: Doses to be administered subcutaneously (SC) twice daily (12 hourly) starting within 72 hours of ictus (onset of symptoms) for a maximum of 21 days from ictus (or sooner if discharged from neurosurgical centre).
Study: NCT02633163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Mesenchymal Stem Cells (MSCs)
Description: Participants will receive a single IV infusion of Mesenchymal Stem Cells (MSCs) 1 x 10\^6 cells/kg in Plasma-Lyte A solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Mesenchymal Stem Cells (MSCs)
Description: Participants will receive a single IV infusion of Mesenchymal Stem Cells MSCs 5 x 10\^6 cells/kg in Plasma-Lyte A solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Infusion
Description: Participants will receive a placebo infusion that does not contain any mesenchymal stem cells.The placebo infusion will consist of Plasma-Lyte A, which is the same vehicle used to deliver the MSCs in the experimental groups.
Study: NCT04400877

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic examination for venous thromboembolism
Description: Patients who have done a diagnostic examination for suspected VTE (pulmonary embolism och deep venous thrombosis) within the health care system of Region Östergötland. Patients without matching diagnostic examination but with a new diagnosis of pulmonary embolism or deep venous thrombosis during the same time periods will also be taking into account.

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic examination for venous thromboembolism
Description: Patients who have done a diagnostic examination for suspected VTE (pulmonary embolism och deep venous thrombosis) within the health care system of Region Östergötland. Patients without matching diagnostic examination but with a new diagnosis of pulmonary embolism or deep venous thrombosis during the same time periods will also be taking into account.
Study: NCT03962491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Self-Monitoring Surveys + Contingency Management
Description: Asked to complete a brief (5-minute) survey with questions related to pain experience and related measures every day for 28 days using the DynamiCare smartphone app, with the opportunity for monetary rewards for completing daily surveys.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Daily Self-Monitoring Surveys
Description: Asked to complete a brief (5-minute) survey with questions related to pain experience and related measures every day for 28 days using the DynamiCare smartphone app.
Study: NCT02199002

Intervention type: DEVICE
Group type: OTHER
Intervention: multi-pH-impedance manometry catheter
Description: a special catheter will be placed in the esophagus of all study groups. Measurment of pH, impedance and pressure will be performed.

Intervention type: DEVICE
Group type: OTHER
Intervention: multi-pH-impedance manometry catheter
Description: a special catheter will be placed in the esophagus of all study groups. Measurment of pH, impedance and pressure will be performed.

Intervention type: DEVICE
Group type: OTHER
Intervention: multi-pH-impedance manometry catheter
Description: a special catheter will be placed in the esophagus of all study groups. Measurment of pH, impedance and pressure will be performed.

Intervention type: DEVICE
Group type: OTHER
Intervention: multi-pH-impedance manometry catheter
Description: a special catheter will be placed in the esophagus of all study groups. Measurment of pH, impedance and pressure will be performed.

Intervention type: DEVICE
Group type: OTHER
Intervention: multi-pH-impedance manometry catheter
Description: a special catheter will be placed in the esophagus of all study groups. Measurment of pH, impedance and pressure will be performed.
Study: NCT03560297

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SeRenade Parent-Child Music Class
Description: Parent-Child Music Class involving parent training, peer inclusion, and musical play

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed Intervention
Description: Participants receive intervention after delay
Study: NCT00512889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Autologous CTL generated from peripheral blood following culture with MART1/Melan-A peptide pulsed aAPC.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Autologous CTL generated from peripheral blood following culture with MART1/Melan-A peptide pulsed aAPC.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Autologous CTL generated from peripheral blood following culture with MART1/Melan-A peptide pulsed aAPC.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Use of an artificial antigen presenting cell (aAPC) to generate CTL
Description: A genetically modified artificial antigen presenting cell (aAPC) is used in the generation of anti-tumor CTL.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Use of an artificial antigen presenting cell (aAPC) to generate CTL
Description: A genetically modified artificial antigen presenting cell (aAPC) is used in the generation of anti-tumor CTL.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Use of an artificial antigen presenting cell (aAPC) to generate CTL
Description: A genetically modified artificial antigen presenting cell (aAPC) is used in the generation of anti-tumor CTL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF will be used as an immune activator and combined with the infusion of MART1/Melan-A specific CTL.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Irradiation of cutaneous tumor lesion
Description: Irradiation of cutaneous melanoma lesion will be combined with the infusion of MART1/Melan-A specific CTL.
Study: NCT05164003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORETOX®
Description: Up to a total of 360U of the IP was allowed to be injected at three flexors; wrist, elbow and finger.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX®
Description: Up to a total of 360U of the comparator was allowed to be injected at three flexors; wrist, elbow and finger.
Study: NCT02345135

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood collection
Description: In all patients with Ataxia telangiectasia blood was collected at each visit date to determine blood count, lymphocyte subpopulation count and immunoglobulin levels in serum (IgA, IgG, IgM, IgE), as well as alpha feto protein (AFP).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lung function measurement
Description: In all patients - Ataxia telangiectasia and healthy controls - a lung function measurement was done to determine vital capacity (VC), forced expiratory volume in 1 second (FEV1), peak expiratory flow (PEF) and Tiffenau index.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lung function measurement
Description: In all patients - Ataxia telangiectasia and healthy controls - a lung function measurement was done to determine vital capacity (VC), forced expiratory volume in 1 second (FEV1), peak expiratory flow (PEF) and Tiffenau index.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom diary
Description: All patients - Ataxia telangiectasia and healthy controls - were requested to keep a symptom diary for the months September to March of the years 2012/2013 and 2013/2014 to determine days with symptoms as coughing during day and night, cold and fever, as well missing days at kindergarten/school/work, intake of medication (especially antibiotic treatment) and hospitalisations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom diary
Description: All patients - Ataxia telangiectasia and healthy controls - were requested to keep a symptom diary for the months September to March of the years 2012/2013 and 2013/2014 to determine days with symptoms as coughing during day and night, cold and fever, as well missing days at kindergarten/school/work, intake of medication (especially antibiotic treatment) and hospitalisations.